Novel biomarkers are necessary to further the development of treatments for neurodegenerative diseases like Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease with advanced and emerging technologies being crucial for their identification and validation in both tissue and fluid samples.
• Tissue samples can be spatially profiled using a range of techniques, including the GeoMx Digital Spatial Profiler to examine transcriptomic or proteomic profiles of specific regions and mass spectrometry imaging to examine a range of molecules including metabolites and
lipids. The outputs from these technologies can be overlaid to examine variations between diseased and control samples.
• Liquid samples like plasma or cerebrospinal fluid can be used to track